NeuroPace, Inc. (Nasdaq: NPCE), a commercial stage medical device company focused on transforming the lives of people living with epilepsy, today announced the first patient implanted in the NAUTILUS clinical study.
Oct 10, 2022 | tpmg.proIn August last year, NeuroPace launched its nSight Platform.
Oct 20, 2022 | livinwellife.com